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Rationale: Optimal risk prediction of early clinical deterioration in community-acquired pneu-
monia (CAP) remains unresolved. We prospectively examined the predictive value of the new
biomarkers copeptin and proadrenomedullin (MR-proADM) in comparison to clinical scores and
inflammatory markers to predict early high risk prognosis in CAP.
Methods: 51 consecutive hospitalised adult patients were enrolled. We measured CRB-65- and
PSI-scores, the ATS/IDSA 2007 minor criteria to predict ICU-admission and the biomarkers CRP,
procalcitonin, copeptin and MR-proADM on admission. Predefined outcome parameters were
combined mortality or ICU-admission after 7 days and clinical instability after 72 h.
Results: Copeptin was the only biomarker significantly elevated in patients with either adverse
short term outcome (p Z 0.003). According to ROC-curve analysis, copeptin predicted ICU
admission or death within 7 days (AUC 0.81, cut-off 35 pmol/l: sensitivity 78%, specificity
79%) and persistent clinical instability after 72 h (AUC 0.74). In Kaplan-Meier-analysis patients
with high copeptin showed lower ICU-free survival within 7 days (p Z 0.001). The diagnostic
accuracy of copeptin was superior to the CRB-65 score and comparable to the PSI-score and
the ATS/IDSA minor criteria. If copeptin was included as additional minor criterion for
combined 7-day mortality or ICU-admission, the diagnostic accuracy of the minor criteria
was significantly improved (p Z 0.045).51 4584538; fax: þ49 351 4585892.
iklinikum-dresden.de (M. Kolditz).
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Copeptin in community-acquired pneumonia 1321Conclusion: Copeptin predicts early deterioration and persistent clinical instability in hospita-
lised CAP and improves the predictive properties of existing clinical scores. It should be eval-
uated within a biomarker guided strategy for early identification of high risk CAP patients who
most likely benefit from early intensified management strategies.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Community acquired pneumonia (CAP) is associated with
a high risk of developing respiratory failure or severe sepsis
with organ dysfunction or shock, resulting in high mortality
rates in hospitalised patients. Initial risk stratification is
required to guide management and treatment decisions by
a disease severity based approach. International guidelines
recommend prognostic scores to support clinical decision
on management as outpatient, inpatient or admission to
ICU. The most established score systems are the PSI and
CRB-65 scores, which perform comparably for mortality
prediction and identification of low risk patients suitable
for an outpatient management strategy.1e4
However, accurate mortality prediction does not auto-
matically lead to accurate identification of patients
benefiting from early aggressive management strategies
like early goal directed treatment, close monitoring for
organ failure or ICU referral. Both the CRB-65 and PSI scores
lack accuracy for the prediction of high risk situations
resulting in ICU admission.5
If patients present to the hospital with manifest respi-
ratory failure requiring mechanical ventilation or manifest
septic shock requiring vasopressor use, direct ICU trans-
ferral and treatment is easy to recognize.6 In patients not
presenting with these major criteria for ICU admission,
prediction of clinical deterioration and/or persisting clin-
ical instability is more controversial albeit of particular
potential benefit. Therefore, additional scoring systems
have been proposed like the new American Thoracic Society
(ATS)/Infectious Diseases Society of America (IDSA)-rec-
ommended rule, incorporating 9 minor criteria to identify
the need for early intensive management.6 However, these
criteria still fail to identify a significant proportion of
patients with early deterioration and have poor positive
predictive values for ICU-admission.5,7e9 Thus, identifying
patients with a high benefit from initial intensive manage-
ment strategies in CAP remains an important task to be
done.10
Biomarkers have been found to improve risk stratifica-
tion and management decisions in CAP. Procalcitonin (PCT)
has been demonstrated to provide additional information
by identifying low risk patients,11 as parameter to judge
treatment response when sequentially measured during
treatment12 and as tool to guide antibiotic treatment
duration.13 Recently, new biomarkers like midregional
proadrenomedullin (MR-proADM) and proarginin-
vasopressin (copeptin) have been associated with even
superior prediction of 28-day mortality or complications
within 30 days in CAP.14e16 However, these studies focused
on mid- and long-term mortality to identify low risk
patients, and data on clinical endpoints reflecting shortterm high risk situations like early clinical deterioration or
persisting clinical instability are rare17 and absent for
newer biomarkers, although they would represent more
relevant endpoints to guide initial intensified management
strategies. Recent data showed, that clinical deterioration
resulting in treatment failure, ICU-admission or death
occurs early in the hospital course: It was demonstrated,
that treatment failure related to CAP occurs within the first
7 days in more than 90% of cases,18 and that there is
a striking excess mortality in the first 7 days after hospital
admission.19 Thus, risk stratification to identify patients
benefiting from early intensified monitoring and manage-
ment strategies should focus on potentially modifiable
clinical adverse events during this most vulnerable early
phase after hospitalisation.
Therefore, the aim of this study was to prospectively
evaluate the new biomarkers MR-proADM and copeptin and
the inflammatory biomarkers leukocyte count (WBC), C-
reactive protein (CRP) and PCT in comparison to the CRB-65
and PSI-scores and the ATS/IDSA- minor criteria for the
prediction of an early (within 7 days) high risk prognosis in
CAP-patients initially hospitalised at the emergency
department or normal ward.
Methods
51 consecutive adult patients, hospitalised for at least 24 h
at the emergency department or the normal ward because
of CAP were prospectively enrolled in the study. CAP was
defined as presence of a new infiltrate on chest radiography
and at least one of the following: fever (38.3 C), cough,
presence of purulent sputum or focal chest signs on
auscultation. Patients were excluded from the study, if one
of the following was present: nosocomial pneumonia,
admission to the ICU within the first 24 h, documented
treatment limitation, immunosuppression including
concomitant medication with systemic steroids, active
tuberculosis and pregnancy. The study protocol was
approved by the local ethics committee. Informed consent
was obtained from the participants.
Disease severity on admission was calculated according
to the CRB-65- and PSI-scores1,2 and the 9 minor criteria to
guide ICU-admission by the ATS/IDSA 2007 guideline.6
On the morning after hospital admission (day 1) venous
blood samples were collected and serum and plasma was
stored frozen at 20 C. CRP was detected by a particle
enhanced immunoturbidimetric assay (Roche Diagnostics
GmbH, Mannheim, Germany), PCT by an enzyme-labelled
sequential chemiluminescent immunoassay (LIA, Brahms
GmbH, Hennigsdorf, Germany) and MR-proADM by an
automated immunofluorescent assay (BRAHMS MR-proADM
KRYPTOR, BRAHMS GmbH, Hennigsdorf, Germany).
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immunoluminometric assay, as described elsewhere,20
except that the capture antibody was replaced by
a murine monoclonal antibody, leading to a higher sensi-
tivity (<0.4 pmol/l).
All laboratory measurements were performed blinded
for any clinical and outcome parameters. In 3 patients (6%,
all ICU-free survivors at day 7) only serum samples (and no
plasma) had been frozen after blood collection, thus MR-
proADM was analysed in the remaining 48 patients. The
other biomarkers were determined in all included patients.
Antibiotics were administered for empirical therapy as
recommended by the German guideline of CAP.21
Predefined short-term outcome parameters were (1)
combined ICU-admission or mortality at day 7 after hospital
admission and (2) clinical instability 72 h after blood
collection. Clinical instability was defined as absence of
one of the following criteria defining clinical stability:
Heart rate  100/min, respiratory rate  24/min, systolic
blood pressure  90 mmHg, temperature  37.8 C, ability
to eat, oxygen saturation  90%, return to baseline mental
status.22
Data of biochemical analyses are presented as median
(interquartile range). Medians were compared using the
non-parametric ManneWhitney test. Receiver operating
characteristic (ROC) curve analysis was used to determine
the diagnostic properties of predictive parameters, optimal
cutoff values were determined by Youdens index. Statis-
tical comparisons between the areas under the curve (AUC)
were calculated according to the Hanley and McNeil
method23 using MedCalc statistical software. To compare
the additive value of copeptin and the clinical scores,
a binary logistic regression model of both parameters was
used. To assess the influence of copeptin concentrations on
ICU-free early mortality, we produced a KaplaneMeier
survival curve, comparison between the groups was done by
log-rank test. A p-value of 0.05 (two-sided) was consid-
ered statistically significant. Statistical analyses were per-
formed with SPSS for Windows, version 17.0 (SPSS Inc.,
Chicago, IL, USA).Results
The baseline and disease severity data of the 51 patients
are shown in Table 1.
A microbiological diagnosis could be established in 19
patients (37%), with S. pneumoniae being the most
frequent pathogen (42%), followed by S. aureus and E. coli
(16% each). Initial empirical antimicrobial therapy con-
sisted of fluoroquinolone monotherapy in 19 (37%), beta-
lactam monotherapy in 18 (35%), and a betalactam
combined with either a macrolide in 7 (14%), a fluo-
roquinolone in 6 (12%) or clindamycin in 1 (2%) patients.
6 patients (12%) died within the first 7 days of hospital
admission after a median of 2.5 days (range 2e6). Causes of
dead as judged by the attending physicians in 4 of them
were CAP-related respiratory failure or septic organ
dysfunction and septic shock. One patient additionally
suffered from acute decompensated heart failure, and one
patient experienced acute cardiac arrest without any pre-
known cardiac comorbidity. Three additional patients (6%)were admitted to the ICU at days 1, 2 and 3 after hospital
admission because of respiratory failure and/or septic
shock from CAP, who finally survived. 25 patients (49%) did
not reach clinical stability at the morning of day 4 of
hospital admission (36 h after blood collection).
Results of the measured serum and plasma biomarkers
according to the predefined outcomes are shown in Table 1.
Although median concentrations of PCT and MR-proADM
tended to be higher in patients with early clinical deterio-
ration or persistent clinical instability, there was no
significant difference between the groups. In contrast,
serum copeptin was significantly higher in patients with
either adverse outcome (48 vs. 17 and 38 vs. 15 pmol/l,
respectively; p Z 0.003 each, Fig. 1). In fact, besides the
PSI-score and the ATS/IDSA minor criteria, copeptin was the
only parameter included in our study cohort, which showed
significant differences for patients with early clinical
deterioration requiring ICU admission or death (Table 1).
Clinical instability beside elevated copeptin levels addi-
tionally was associated with older age (p Z 0.03), longer
hospital stay (p Z 0.006), more minor criteria (p < 0.001)
and higher CRB-65 (p Z 0.004) and PSI-scores (p  0.001),
but not with other biomarkers.
The diagnostic value of serum copeptin was calculated by
ROC-curve analysis (Fig. 2). Topredict ICUadmissionor death
within the first 7 days after hospital admission, the AUC was
0.81 (95%-CI 0.66e0.97) with an optimal cut-off value of
35 pmol/l (sensitivity 78%, specificity 79%, þLR 3.6, LR
0.28, PPV 40%, NPV 92%). To predict persistent clinical
instability after 36 h, the AUC was 0.74 (95%-CI 0.60e0.88)
with an optimal cut-off value of 25 pmol/l (sensitivity 60%,
specificity 81%, þLR 3.1, LR 0.5, PPV 75%, NPV 68%). Cor-
responding AUCs of the other biomarkers for both endpoints
were the following: MR-proADM 0.67 (optimal cut-off for 7
day ICU admission/mortality 1.05 nmol/l: sensitivity 67%,
specificity 85%, þLR 4.3, LR 0.4) and 0.61, PCT 0.59 and
0.59, CRP 0.54 and 0.56 and WBC 0.59 and 0.51.
The predictive value of serum copeptin was confirmed
by Kaplan-Meier-analysis, showing a significantly lower ICU-
free survival probability within the first 7 days in patients
with a serum copeptin >35 pmol/l (p Z 0.001, Fig. 3).
The AUC for prediction of ICU admission or death within
7 days by the PSI-score was 0.75, which was not significantly
inferior to that of copeptin (p Z 0.36). The combined use
of the PSI-score and copeptin improved the AUC to 0.83
(p Z 0.19 in binary logistic regression analysis). The PSI
score predicted clinical instability with an AUC of 0.83,
which was not significantly superior to that of copeptin
(p Z 0.21). The addition of copeptin to the PSI-score
resulted in a combined AUC of 0.84 (p Z 0.23 in binary
logistic regression analysis).
The prediction of ICU admission or death within 7 days
by the CRB-65 score in our cohort was significantly inferior
to that of copeptin (AUC Z 0.57, p Z 0.018), and the
addition of the CRB-65 score to copeptin did not improve
the prediction of copeptin alone (combined AUC 0.78). The
CRB-65 score predicted clinical instability with an AUC of
0.73, which was comparable to that of copeptin. The
addition of copeptin to the CRB-65-score to predict clinical
instability significantly improved the diagnostic accuracy,
as shown in binary logistic regression analysis (combined
AUC 0.80, p Z 0.049).
Table 1 Characteristics of the study patients and laboratory values according to outcome (bold: p< 0.05).
All patients ICU or death within 7 days Cli nstable after 72 h
N Z 51 Yes, N Z 9 No, N Z 42 p-value Ye 25 No, N Z 26 p-value
Male, No. (%) 25 (49) 3 (33) 22 (52) 0.39 14 (54) 0.49
Age, median (IQRa) 72 (41e80) 74 (55e84) 72 (40e79) 0.22 7 e83) 67 (36e79) 0.034
Comorbidities, No. (%) 39 (76) 8 (89) 31 (74) 0.49 18 (69) 0.22
COPD, No. (%) 3 (6) 1 (11) 2 (5) 0.78 2 (8) 0.58
Smoking history, No. (%) 17 (33) 2 (22) 15 (36) 0.54 11 (42) 0.17
Antibiotic pre-treatment,
No. (%)
11 (22) 3 (33) 8 (19) 0.69 7 (27) 0.22
Pathogen established,
No. (%)
19 (37) 4 (44) 15 (36) 0.69 9 (35) 0.69
Bacteraemia, No. (%) 6 (12) 1 (11) 5 (12) 0.98 3 (12) 0.81
LOS,b median (IQR) 8 (4e12) 4 (2e42) 8 (5e11) 0.44 1 19) 7 (3e9) 0.006
CRB-65-Score,
median (IQR)
2 (1e2) 2 (1e2) 2 (1e2) 0.54 3) 1 (0e2) 0.004
PSI-Score, median (IQR) 109 (76e144) 134 (118e164) 103 (61e140) 0.02 13 6e163) 87 (36e109) <0.001
ATS/IDSAc
minor criteria,
median (IQR)
2 (1e3) 4 (2.5e4) 1 (1e3) 0.003 4) 1 (0e2) <0.001
Leucocytes (GPt/l),
median (IQR)
13.4 (9.3e18.2) 15 (8.1e23.3) 12.8 (9.2e17) 0.44 13 e17.5) 13.5 (9.2e18.8) 0.88
CRP,d (mg/l)
median (IQR)
227 (134e295) 220 (133e305) 229 (133e290) 0.73 2 e305) 221 (118e290) 0.45
PCT,e (ng/ml)
median (IQR)
1.7 (0.17e5.5) 2.6 (0.57e12) 1.6 (0.15e5.5) 0.43 2 9e9.7) 1.5 (0.14e4.2) 0.26
Copeptin, (pmol/l)
median (IQR)
18.3 (11.5e41.1) 47.9 (27.9e160) 17 (11e33) 0.003 37 .3e60.7) 14.6 (10.6e22.4) 0.003
MR-proADM,f (nmol/l)
median (IQR)
0.42 (0.06e1.1) 1.1 (0.07e5.2) 0.37 (0.05e0.74) 0.11 0. 6e1.6) 0.37 (0.06e0.7) 0.18
a IQR Z interquartile range.
b LOS Z length of stay.
c ATS/IDSA Z American Thoracic Society/Infectious Diseases Society of America.
d CRP Z C-reactive proteine.
e PCT Z procalcitonin.
f MR-proADM Z midregional proadrenomedullin.
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Figure 1 Box-plots showing serum concentrations of copeptin according to the predefined outcome parameters (a) ICU-admission
or mortality at day 7 after hospital admission and (b) Clinical instability after 72 h.
1324 M. Kolditz et al.The AUC for prediction of ICU admission or death within
7 days by the 9 ATS/IDSA minor criteria was 0.81, which was
identical to the AUC of copeptin. The optimal cut-off in our
cohort was >2 criteria (sensitivity 78%, specificity 74%),
which resembles the cut-off suggested by the guideline.6
The addition of copeptin >35 pmol/l as 10th minorcriterion significantly improved the AUC to 0.85 (>2
criteria: sensitivity 89%, specificity 67%, pZ 0.045 in binary
logistic regression analysis; Fig. 4a). The AUC for prediction
of clinical instability by the 9 ATS/IDSA minor criteria was
0.78, which was not significantly superior to the AUC of
copeptin (p Z 0.61). The optimal cut-off was >2 criteria
Figure 2 Receiver operating characteristic curves comparing
copeptin and the clinical scores for predicting (a) ICU-
admission or mortality at day 7 after hospital admission and
(b) Clinical instability after 72 h.
Copeptin in community-acquired pneumonia 1325(sensitivity 60%, specificity 88%). The addition of copeptin
> 25 pmol/l as 10th minor criterion improved the AUC to
0.81 (p Z 0.054 in binary logistic regression analysis,
Fig. 4b).
Discussion
The main findings of our study are, that increased copeptin
levels are associated with early clinical deterioration
resulting in ICU-admission or death and persistent clinicalinstability in hospitalised CAP patients and that this
biomarker improves or even outperforms the prognostic
value of recommended clinical scores for early high risk
prediction. This complements previous studies on prog-
nostic cardiovascular biomarkers in CAP14e16 by two rele-
vant new findings: Whereas the focus in former studies was
prediction of mid- and long-term mortality after 28e180
days, which rather allows identification of low risk patients
in the disease course, our study for the first time provides
data on early clinical high risk prediction to identify
patients at risk of clinical deterioration and/or persistent
instability during the first days after hospital admission who
potentially would benefit from direct initiation of more
aggressive monitoring and treatment strategies in order to
improve their outcome. And while MR-proADM tended to
perform superior for mortality prediction after 28e180 days
in previous studies,15,16 according to our data copeptin
seems to be superior in identifying these early high risk
patients.
The optimal copeptin cut-off values to predict adverse
outcomes from our data, e.g. ICU admission or death within
7 days or persistent clinical instability after 36 h, were 35
and 25 pmol/l, respectively. They closely resemble that
from a recent, large study, evaluating copeptin as
biomarker to predict 28-day mortality in 1740 CAP patients
and finding an optimal threshold of 29 pmol/l (AUC 0.84).14
These cut-off values are well above the 97th percentile of
12 pmol/l found in healthy volunteers.24 Copeptin is
cleaved from the vasopressin precursor and thus reflects
haemodynamic and osmoregulatory antidiuretic effects as
a stress- and volume-dependent biomarker. Copeptin has
been associated with diagnosis and prognosis in cardiovas-
cular diseases like heart failure or acute coronary syndrome
and renal disease.24 On the other hand, in patients with
septic shock its levels are strongly elevated and associated
with poorer survival.25 In high risk CAP, elevated levels of
copeptin might thus either reflect the degree of progressive
septic disease or decompensating/newly developing
cardiac or renal disease, which all demand more intensive
monitoring and management.
Several clinical scores have been evaluated for mortality
prediction in CAP, with the CRB-65 and PSI scores being the
most frequently recommended tools. However, mortality
prediction might not be optimal to identify patients at risk
for deteriorating or nonresponding disease reflecting
respiratory insufficiency, septic organ dysfunction, shock or
decompensating underlying disease. These carry a high
demand on and benefit of intensified management strate-
gies, which makes their early detection crucial. The
endpoint of combined mortality or ICU admission within the
first 7 days after hospital admission, which was used in our
study, more accurately identifies the group of patients who
initially needs closer monitoring and intensified manage-
ment. Also, failure to achieve clinical stability after 72 h
represents another relevant outcome parameter, as it
represents possible treatment nonresponse and therefore
the need for intensified monitoring and diagnostic re-eval-
uation.6 Clinical stability in CAP is well defined by clinical
parameters and reflects a very low risk of the reoccurrence
of instability or death.22,26 If clinical stability is reached,
switch to oral antibiotics and hospital discharge can be
considered.6,27
Figure 3 KaplaneMeier curves showing ICU-free survival
within the first 7 days after hospital admission stratified by
serum copeptin level (>35 pmol/l). P-value determined by log
rank test.
Figure 4 Receiver operating characteristic curves for the
combined use of the ATS/IDSA minor criteria and copeptin for
predicting (a) ICU-admission or mortality at day 7 after hospital
admission and (b) Clinical instability after 72 h.
1326 M. Kolditz et al.In our study, the CRB-65 score was significantly inferior
to the biomarker copeptin in predicting combined mortality
or ICU admission within 7 days and its predictive value for
clinical instability after 72 h was significantly improved by
the addition of copeptin. Moreover, copeptin alone showed
a predictive accuracy for both endpoints which was
comparable to that of the difficult to calculate PSI-score,
consisting of 20 parameters.1 The ATS/IDSA criteria reflect
different mechanisms of disease progression in CAP and
have been developed to identify patients in need of ICU
treatment.6 However, the two major criteria (mechanical
ventilation and vasopressor dependent shock) rather
represent endpoints by themselves than risk scoring
parameters and the minor criteria still have poor positive
predictive values while missing a relevant subset of
patients who deteriorate in the course and carry an
exceptional poor prognosis.5e9 Complementing these
criteria by new biomarkers might be a promising approach.
In our cohort, the minor criteria identified patients who
deteriorate in the course with a sensitivity of 78%, reas-
suring our finding of the same optimal cut-off of >2 criteria
as suggested by the guideline.6 By the addition of copeptin
as 10th criterion, the diagnostic accuracy of this score
could be significantly improved, mainly by identifying more
patients who deteriorate in the course (sensitivity 89%).
Causes for persistent clinical instability, clinical deteri-
oration or death in CAP are complex and a result of
heterogeneous interactions reflecting inflammation and
sepsis with developing shock or organ dysfunction as well as
underlying or decompensating chronic disease and stress
response. So it has been shown, that cardiac complications
occur frequently in CAP, especially in the setting of treat-
ment failure.18,28 Therefore, monitoring inflammatory
biomarkers like CRP and PCT alone probably might not
sufficient to account for the complex interactions leadingto poor prognosis in CAP.15,29 This is confirmed by our data,
showing poor prognostic accuracy for the measured
inflammatory parameters in predicting short term prog-
nosis. Biomarkers reflecting cardiovascular impairment like
copeptin or multiple regulatory effects like MR-proADM
recently have been shown to outperform inflammatory
markers like CRP and PCT regarding their prognostic value
in CAP.14,15 Both, MR-proADM and copeptin are potent
Copeptin in community-acquired pneumonia 1327biomarkers for predicting mid- and longterm (28 and 180
days) mortality in CAP and to improve the prognostic
properties of clinical scores.14,15,30 However, prediction of
mortality and complications after 28 or even 180 days might
provide data on the identification of low risk patients
suitable for earlier discharge from hospital, but it probably
does not reflect optimal endpoints to guide early intensified
management strategies for improving the outcome of
patients with early clinical deterioration or persistent
instability. Our data add to these references by showing
that copeptin additionally predicts short term high risk
situations, whereas MR-proADM probably rather reflects
prognosis within a broader time frame. Taken these data
together, it could be hypothesized, that different
biomarkers might be used as complementary tools to
predict different management decisions in CAP: Whereas
PCT has been validated to guide antibiotic treatment in
CAP13 and MR-proADM might be a tool to predict low risk for
mortality or complications within the following weeks
allowing earlier hospital discharge,30 copeptin is a candi-
date marker for identifying patients with a high risk of early
clinical deterioration who might benefit from early inten-
sified management like cardiovascular and oxygenation
monitoring, early goal directed treatment, early antibiotic
combination therapy and even adjuvant treatment options.
However, a benefit of such biomarker driven strategies, at
least for the latter two scenarios, still has to be confirmed
by large interventional trials.
The main limitation of our study is the small sample size
in a single institution study, clearly demanding for larger
studies confirming our finding and the suggested cut-off
value for copeptin. In order to implement a biomarker-
driven identification of patients with a high risk of early
clinical deterioration or nonresponse into clinical practice,
a large prospective interventional trial assessing the guid-
ance of more intensive monitoring and management strat-
egies based on a combined risk stratification tool consisting
of clinical factors and a biomarker like copeptin should be
performed.
Strengths of this study include the well-defined patient
cohort, the robust and strictly controlled endpoints, the
data completeness for various recommended clinical
scores, and the exclusion of patients with end of life
decisions, which often obscure interpretations of observa-
tional or retrospective studies.19
In conclusion, the cardiovascular biomarker copeptin
predicts early deterioration and persistent clinical insta-
bility in hospitalised CAP patients. It improves the predic-
tive properties of existing clinical scores and thus
represents a promising candidate to be evaluated within
a biomarker guided strategy for early identification of high
risk CAP patients, who most likely would benefit from early
intensified monitoring and management strategies in order
to improve their outcome.
Conflicts of interest statement
MK and GH received honoraria from BRAHMS/ThermoFisher
for lectures and advisory board activities.
The other authors have no conflicts of interest to
declare.References
1. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE,
et al. A prediction rule to identify low-risk patients with
community-acquiredpneumonia.NEngl JMed 1997;336:243e50.
2. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T. CRB-65 predicts
death from community-acquired pneumonia. J Intern Med
2006;260:93e101.
3. Loke YK, Kwok CS, Niruban A, Myint PK. Value of severity scales
in predicting mortality from community-acquired pneumonia:
systematic review and meta-analysis. Thorax 2010;65:884e90.
4. Chalmers JD, Singanayagam A, Akram AR, Mandal P, Short PM,
Choudhury G, et al. Severity assessment tools for predicting
mortality in hospitalised patients with community-acquired
pneumonia. Systematic review and meta-analysis. Thorax
2010;65:878e83.
5. Chalmers JD, Mandal P, Singanayagam A, Akram AR,
Choudhury G, Short PM, Hill AT. Severity assessment tools to
guide ICU admission in community-acquired pneumonia:
systematic review and meta-analysis. Intensive Care Med 2011;
37:1409e20.
6. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG,
Campbell GD, Dean NC, et al. Infectious Diseases Society of
America/American Thoracic Society Consensus guidelines on
the management of community-acquired pneumonia in adults.
Clin Infect Dis 2007;44:S27e72.
7. Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M,
Piner R, et al. Severe community-acquired pneumonia: vali-
dation of the Infectious Diseases Society of America/American
Thoracic Society guidelines to predict an intensive care unit
admission. Clin Infect Dis 2009;48:377e85.
8. Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late
admission to the ICU in patients with community-acquired
pneumonia is associated with higher mortality. Chest 2010;
137:552e7.
9. Renaud B, Santin A, Coma E, Camus N, Van Pelt D, Hayon J,
et al. Association between timing of intensive care unit
admission and outcomes for emergency department patients
with community-acquired pneumonia. Crit Care Med 2009;37:
2867e74.
10. Ewig S, Woodhead M, Torres A. Towards a sensible compre-
hension of severe community-acquired pneumonia. Intensive
Care Med 2011;37:214e23.
11. Kru¨ger S, Ewig S, Marre R, Papassotiriou J, Richter K, von
Baum H, et al. Procalcitonin predicts patients at low risk of
death from community-acquired pneumonia across all CRB-65
classes. Eur Respir J 2008;31:349e55.
12. Charles PE, Tinel C, Barbar S, Aho S, Prin S, Doise JM, et al.
Procalcitonin kinetics within the first days of sepsis: relation-
ship with the appropriateness of antibiotic therapy and the
outcome. Crit Care 2009;13. R38.
13. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D,
Huber PR, et al. Procalcitonin guidance of antibiotic therapy in
community-acquired pneumonia: a randomized trial. Am J
Respir Crit Care Med 2006;174:84e93.
14. Kru¨ger S, Ewig S, Kunde J, Hartmann O, Suttorp N, Welte T.
Pro-atrial natriuretic peptide and pro-vasopressin for predict-
ing short-term and long-term survival in community-acquired
pneumonia: results from the German Competence Network
CAPNETZ. Thorax 2010;65:208e14.
15. Kru¨ger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T.
Cardiovascular and inflammatory biomarkers to predict short-
and long-term survival in community-acquired pneumonia:
results from the German Competence Network CAPNETZ. Am J
Respir Crit Care Med 2010;182:1426e34.
16. Schuetz P, Wolbers M, Christ-Crain M, Thomann R,
Falconnier C, Widmer I, et al. Prohormones for prediction of
1328 M. Kolditz et al.adverse medical outcome in community-acquired pneumonia
and lower respiratory tract infections. Crit Care 2010;14.
R106.
17. Mene´ndez R, Martinez R, Reyes S, Mensa J, Polverino E,
Filella X, et al. Stability in community-acquired pneumonia:
one step forward with markers? Thorax 2009;64:987e92.
18. Aliberti S, Amir A, Peyrani P, Mirsaeidi M, Allen M, Moffett BK,
et al. Incidence, etiology, timing, and risk factors for clinical
failure in hospitalized patients with community-acquired
pneumonia. Chest 2008;134:955e62.
19. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J,
Bischoff H, et al. New perspectives on community-acquired
pneumonia in 388 406 patients. Results from a nationwide
mandatory performance measurement programme in health-
care quality. Thorax 2009;64:1062e9.
20. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for
the measurement of copeptin, a stable peptide derived from
the precursor of vasopressin. Clin Chem 2006;52:112e9.
21. Ho¨ffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K, et al.
Epidemiology, diagnosis, antimicrobial therapy and manage-
ment of community-acquired pneumonia and lower respiratory
tract infections in adults. Guidelines of the Paul-Ehrlich-
Society for Chemotherapy, the German Respiratory Society,
the German Society for Infectiology and the Competence
Network CAPNETZ Germany. Pneumologie 2009;63. e1e68.
22. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN,
Obrosky DS, Singer DE. Time to clinical stability in patients
hospitalized with community-acquired pneumonia: implica-
tions for practice guidelines. JAMA 1998;279:1452e7.23. Hanley JA, McNeil BJ. A method of comparing the areas under
receiver operating characteristic curves derived from the same
cases. Radiology 1983;148:839e43.
24. Morgenthaler NG. Copeptin: a biomarker of cardiovascular and
renal function. Congest Heart Fail 2010;16(Suppl. 1):S37e44.
25. Morgenthaler NG, Mu¨ller B, Struck J, Bergmann A, Redl H,
Christ-Crain M. Copeptin, a stable peptide of the arginine
vasopressin precursor, is elevated in hemorrhagic and septic
shock. Shock 2007;28:219e26.
26. Aliberti S, Peyrani P, Filardo G, Mirsaeidi M, Amir A, Blasi F,
Ramirez JA. Association between time to clinical stability and
outcomes after discharge in hospitalized patients with
community-acquired pneumonia. Chest 2011;140:482e8.
27. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch
from intravenous to oral cephalosporins in the treatment of
hospitalized patients with community-acquired pneumonia.
Arch Intern Med 1995;155:1273e6.
28. Corrales-Medina VF, Suh KN, Rose G, Chirinos JA, Doucette S,
CameronDW,FergussonDA.Cardiaccomplications inpatientswith
community-acquired pneumonia: a systematic review and meta-
analysis of observational studies. PLoS Med 2011;8. e1001048.
29. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M,
Zimmerli W, Mueller B. Prognostic value of procalcitonin in
community-acquired pneumonia. Eur Respir J 2011;37:384e92.
30. Albrich WC, Dusemund F, Ru¨egger K, Christ-Crain M,
Zimmerli W, Bregenzer T, et al. Enhancement of CURB65 score
with proadrenomedullin (CURB65-A) for outcome prediction in
lower respiratory tract infections: derivation of a clinical
algorithm. BMC Infect Dis 2011;11:112.
